5 research outputs found
Description of pro- and anti-inflammatory markers between viremia groups.
<p>All patients were male, non smokers.</p><p>Medians (25th and 75th %tiles) were adjusted by age, hypertension, and duration of antiretroviral therapy using quantile regression.</p><p>*Significance determined using a two-tailed t-test based on estimated variance.</p><p>**Thresholds for biochemical markers were included in the summary statistic and calculated using the median between the commercial threshold given and 0.</p><p>D – detectable; UD – undetectable; us-CRP – ultra-sensitive C-reactive protein; IL – interleukin; HMW – high molecular weight; ICAM-1 – intercellular adhesion molecule-1; I-TAC – interferon inducible T-cell alpha chemoattractant; IP-10 – inducible protein-10; VCAM-1 – vascular cell adhesion molecule-1; MCP-1 – monocyte chemoattractant protein-1.</p><p>Description of pro- and anti-inflammatory markers between viremia groups.</p
Total and common carotid artery intima media thicknesses between viremia groups.
<p>All patients were male, non smokers.</p><p>*Difference in intima media maximal thickness between groups.</p><p>**Hypertension was defined by prior physician‘s diagnosis or systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg.</p><p>c-IMT – carotid intima media thickness; cca-IMT – common carotid artery intima media thickness; D – detectable; UD – undetectable; SBP – systolic blood pressure; HDL – high-density lipid; LDL – low-density lipid; CVD – cardiovascular disease; HOMA-IR – homeostatic model assessment of insulin resistance; ART – antiretroviral therapy; VL – viral load; PI – protease inhibitors.</p><p>Total and common carotid artery intima media thicknesses between viremia groups.</p
Demographic and HIV characteristics between viremia groups.
<p>All patients were male, non smokers.</p><p>*Significance determined using a Kruskal-Wallis equality-of-populations rank test for continuous variables and Pearson χ<sup>2</sup> test or Fisher's Exact test for categorical variables;</p><p>**number (%);</p><p><sup>†</sup>median (25-75<sup>th</sup>%tile).</p><p><sup>†</sup><sup>†</sup>Medians (25th and 75th %tiles) adjusted by age, hypertension, and duration of ART using quantile regression. Significance determined using a two-tailed t-test based on variance estimations.</p><p>D – detectable; UD – undetectable; HDL – high-density lipid; LDL – low-density lipid; HOMA-IR – homeostatic model assessment of insulin resistance; QUICKI – quantitative insulin sensitivity check index; HIV – human immunodeficiency virus; ART – antiretroviral therapy; cp/mL – copies/mL; VL – viral load; NRTI – nucleos(-t)ide reverse transcriptase inhibitor; NNRTI – non-nucleos(-t)ide reverse transcriptase inhibitor; PI – protease inhibitor; <i>ntp</i> – no test performed.</p><p>Demographic and HIV characteristics between viremia groups.</p
Standardized difference between statin users and non users.
<p>Abbreviations: BMI = body mass index, HCV = hepatitis C virus, HBs = hepatitis B, AIDS = acquired immune deficiency syndrome.</p
Characteristics of the study patients.
<p>Table entries are n (%), mean ± standard deviation, or median (interquartile range), as appropriate.</p><p>Index date: date of MI diagnosis.</p><p>MSM: men having sex with men, BMI: body mass index, AIDS: acquired immune deficiency syndrome, HCV: hepatitis C virus, HBs: hepatitis B surface.</p><p>* p values were calculated including missing data.</p><p><sup>†</sup> Within three months prior to the index date.</p><p>Characteristics of the study patients.</p